ono pharm - OPHLF

OPHLF

Close Chg Chg %
14.83 0.39 2.61%

Closed Market

15.22

+0.39 (2.61%)

Volume: 1.35K

Last Updated:

Jan 27, 2026, 10:45 AM EDT

Company Overview: ono pharm - OPHLF

OPHLF Key Data

Open

$15.22

Day Range

15.22 - 15.22

52 Week Range

9.20 - 15.22

Market Cap

$7.15B

Shares Outstanding

469.91M

Public Float

332.90M

Beta

0.06

Rev. Per Employee

N/A

P/E Ratio

17.08

EPS

$0.89

Yield

350.71%

Dividend

$0.26

EX-DIVIDEND DATE

Mar 30, 2026

SHORT INTEREST

N/A

AVERAGE VOLUME

87.00

 

OPHLF Performance

1 Week
 
0.00%
 
1 Month
 
18.26%
 
3 Months
 
48.20%
 
1 Year
 
3.54%
 
5 Years
 
N/A
 

OPHLF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About ono pharm - OPHLF

Ono Pharmaceutical Co., Ltd. engages in the production, purchase, and sale of internal medicine, patch and injectable medicine. The company was founded by Ichibei Fushimiya in 1717 and is headquartered in Osaka, Japan.

OPHLF At a Glance

Ono Pharmaceutical Co., Ltd.
1-8-2 Kyutaromachi
Osaka, Osaka 541-8564
Phone 81-6-6263-5670 Revenue 3.19B
Industry Pharmaceuticals: Major Net Income 328.28M
Sector Health Technology Employees 4,287
Fiscal Year-end 03 / 2026
View SEC Filings

OPHLF Valuation

P/E Current 17.082
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 15.333
Price to Sales Ratio 1.576
Price to Book Ratio 0.962
Price to Cash Flow Ratio 9.31
Enterprise Value to EBITDA 7.847
Enterprise Value to Sales 1.455
Total Debt to Enterprise Value 0.211

OPHLF Efficiency

Revenue/Employee 744,958.277
Income Per Employee 76,576.602
Receivables Turnover 3.436
Total Asset Turnover 0.486

OPHLF Liquidity

Current Ratio 3.069
Quick Ratio 2.564
Cash Ratio 1.419

OPHLF Profitability

Gross Margin 68.903
Operating Margin 13.019
Pretax Margin 12.16
Net Margin 10.279
Return on Assets 4.992
Return on Equity 6.27
Return on Total Capital 5.284
Return on Invested Capital 5.824

OPHLF Capital Structure

Total Debt to Total Equity 18.746
Total Debt to Total Capital 15.787
Total Debt to Total Assets 13.785
Long-Term Debt to Equity 14.506
Long-Term Debt to Total Capital 12.216
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Ono Pharm - OPHLF

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
3.22B 3.30B 3.48B 3.19B
Sales Growth
+10.29% +2.65% +5.44% -8.25%
Cost of Goods Sold (COGS) incl D&A
858.35M 833.48M 900.24M 993.12M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
157.71M 128.82M 125.61M 176.41M
Depreciation
88.16M 72.23M 69.76M 69.31M
Amortization of Intangibles
69.55M 56.60M 55.85M 107.10M
COGS Growth
+3.24% -2.90% +8.01% +10.32%
Gross Income
2.36B 2.47B 2.58B 2.20B
Gross Income Growth
+13.10% +4.67% +4.57% -14.73%
Gross Profit Margin
+73.31% +74.75% +74.14% +68.90%
2022 2023 2024 2025 5-year trend
SG&A Expense
1.33B 1.34B 1.45B 1.78B
Research & Development
675.29M 703.84M 776.76M 983.05M
Other SG&A
659.62M 639.61M 674.38M 801.70M
SGA Growth
+9.76% +0.64% +8.02% +22.99%
Other Operating Expense
- - - (3.18M)
-
Unusual Expense
67.57M 58.07M 948.67K 10.79M
EBIT after Unusual Expense
955.11M 1.07B 1.13B 404.98M
Non Operating Income/Expense
(19.71M) (5.70M) 2.85M (5.90M)
Non-Operating Interest Income
293.68K 516.75K 7.75M 10.38M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
658.57K 937.53K 727.08K 10.72M
Interest Expense Growth
-12.69% +42.36% -22.45% +1,375.05%
Gross Interest Expense
658.57K 937.53K 727.08K 10.72M
Interest Capitalized
- - - -
-
Pretax Income
934.73M 1.06B 1.13B 388.34M
Pretax Income Growth
-1.73% +13.35% +7.01% -65.75%
Pretax Margin
+29.07% +32.10% +32.57% +12.16%
Income Tax
216.61M 226.03M 247.17M 60.10M
Income Tax - Current - Domestic
89.16M 302.81M 280.08M 138.25M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
127.47M (76.78M) (32.91M) (78.16M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
718.05M 833.53M 886.62M 329.06M
Minority Interest Expense
1.48M 1.40M 429.32K 780.58K
Net Income
716.57M 832.13M 886.19M 328.28M
Net Income Growth
+0.77% +16.13% +6.50% -62.96%
Net Margin Growth
+22.28% +25.21% +25.46% +10.28%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
716.57M 832.13M 886.19M 328.28M
Preferred Dividends
- - - -
-
Net Income Available to Common
716.58M 832.13M 886.18M 328.28M
EPS (Basic)
1.4434 1.7041 1.8462 0.6989
EPS (Basic) Growth
+1.31% +18.06% +8.34% -62.14%
Basic Shares Outstanding
496.46M 488.30M 480.01M 469.69M
EPS (Diluted)
1.4432 1.7037 1.8459 0.698
EPS (Diluted) Growth
+1.31% +18.05% +8.35% -62.19%
Diluted Shares Outstanding
496.53M 488.35M 480.04M 469.77M
EBITDA
1.18B 1.25B 1.26B 592.18M
EBITDA Growth
+16.01% +6.16% +0.41% -52.93%
EBITDA Margin
+36.70% +37.96% +36.15% +18.54%

Ono Pharm in the News